Table 1 Baseline characteristics of the patients
Variables | Training set (n = 139) | External validation set (n = 89) | P value |
|---|---|---|---|
Age(years) | 72(46–89) | 75(51–95) | 0.577 |
Sex | 0.090 | ||
Female | 56(40.2) | 26(29.2) | |
Male | 83(59.7) | 63(70.7) | |
Smoke | 0.237 | ||
Yes | 92(66.1) | 52(58.4) | |
No | 47(33.8) | 37(41.5) | |
ECOG | 0.020 | ||
0 | 72(51.7) | 60(67.4) | |
1 | 67(48.2) | 29(32.5) | |
T stage | 0.183 | ||
T1 | 109(78.4) | 74(83.1) | |
T2 | 25(17.9) | 15(16.8) | |
T3 | 5(3.5) | 0(0.0) | |
Tumor size(cm) | 2.2(1.0-6.1) | 2.1(0.9–4.6) | 0.124 |
Tumor location | 0.293 | ||
Peripheral | 132(94.9) | 87(97.7) | |
Central | 7(5.0) | 2(2.2) | |
Histology | < 0.001 | ||
Adenocarcinoma | 29(20.8) | 42(47.1) | |
Squamous cell carcinoma | 22(15.8) | 10(11.2) | |
Undifferentiated NSCLC | 8(5.8) | 6(6.7) | |
No pathology | 80(57.5) | 31(34.8) | |
SUVmax | 8.7(2.8–28.8) | 6.2(2.9–21.8) | 0.009 |
Radiation dose per fraction (Gy) | 12(7–20) | 10(5-12.5) | < 0.001 |
Total radiation dose (Gy) | 60(48–60) | 50(48–70) | < 0.001 |
BED10(Gy) | 132(83.3–180) | 105(75–119) | < 0.001 |
Distant metastasis | 0.133 | ||
Yes | 37(26.6) | 16(17.9) | |
No | 102(73.3) | 73(82.0) |